Dermalumin C

DermaLumin-C 7 x 2ml

Melanin Correcting Serum to specifically regulate excessive melanin production. Particularly recommended for skin with pigmentation disorders.

$78.00

In stock

Key Benefits
  • Pigmentation Correction: Specifically formulated to reduce dark spots and even out skin tone by regulating melanin production.
  • Rapid Results: Visible improvements in skin tone, texture, and brightness can be seen in as little as two weeks (14 days).
  • Brightening & Anti-inflammatory: Contains a blend of active ingredients, including stabilized Vitamin C, Tranexamic Acid, Azelaic Acid, and Butyl-Resorcinol.
  • Skin Improvement: Promotes a smoother, more radiant surface and supports natural skin regeneration.

 

How to Use
  • Application: Shake the ampoule well before use. Apply the entire 2ml contents to the face, neck, décolleté, and hands after cleansing.
  • Method: Gently pat the serum into the skin until fully absorbed.
  • Timing: These are ideal for use in the morning to boost the effectiveness of SPF and provide a daily glow.
  • Frequency: Can be used as an intensive treatment, with results often seen in 4 weeks.

INCI:

AQUA (WATER), GLYCERIN, TRANEXAMIC ACID, SODIUM ASCORBYL PHOSPHATE, PENTYLENE GLYCOL, PROPANEDIOL, MAGNESIUM ASCORBYL PHOSPHATE, LACTIC ACID, PHYTIC ACID, 4-BUTYLRESORCINOL, SODIUM HYDROXIDE, XANTHAN GUM, CAPRYLHYDROXAMIC ACID, SODIUM HYALURONATE, LINOLENIC ACID.

Key Ingredients
  • Stabilized Vitamin C & Tranexamic Acid: Regulates melanin activity to reduce spots.
  • Azelaic Acid & Butyl-Resorcinol: Provides brightening and anti-inflammatory effects.
  • HyWhite®: Improves skin tone and evenness.
  • Pentylene Glycol: Calms and stabilises sensitive skin.

ACTIVE INGREDIENTS:

• Sodium Ascorbyl Phosphate (SAP)

• Magnesium Ascorbyl Phosphate (MAP)

• α-Linolenic Acid–Modified Hyaluronic Acid

• 1% 4-n-Butylresorcinol

• 2% Phytic Acid

• 3% Tranexamic Acid

ASCORBYL PHOSPHATE (SAP) (INCI: SODIUM ASCORBYL PHOSPHATE)

A stabilised vitamin C ester that gradually converts into ascorbic acid within the skin. It provides antioxidant protection, inhibits tyrosinase, and refines overall skin tone.

MAGNESIUM ASCORBYL PHOSPHATE (MAP) (INCI: MAGNESIUM ASCORBYL PHOSPHATE)

MAP reduces oxidative intermediates in the melanin pathway and directly suppresses tyrosinase activity. In combination with TXA, it enhances tone uniformity through synergistic anti-inflammatory and antioxidant effects.

Evidence: Clinical data on 10% MAP creams show a significant reduction in lentigines and melasma; lower concentrations (1–5%) remain effective when used in combination systems.

α-LINOLENIC ACID–MODIFIED HYALURONIC ACID (INCI: LINOLENIC ACID)

A patented active ingredient composed of ultra–low–molecular-weight hyaluronic acid conjugated with α-linolenic acid. This architecture improves dermal penetration and modulates melanin formation in deeper layers.

Evidence: Manufacturer-sponsored data confirm tyrosinase inhibition and a visible evening of skin tone within four weeks, with excellent tolerance even in sensitive skin.

4-n-BUTYLRESORCINOL (INCI: 4-BUTYLRESORCINOL)

A potent dual inhibitor of tyrosinase and TRP-1, the two central enzymes driving melanin biosynthesis.

Evidence: Randomised split-face studies using 0.1–0.3% formulations demonstrated a marked decrease in melanin index after 4–8 weeks. At 1%, stronger inhibition is expected.

PHYTIC ACID (INCI: PHYTIC ACID)

A natural chelating agent that binds copper and iron ions—both essential cofactors of tyrosinase. By limiting their availability, phytic acid indirectly suppresses melanogenesis while providing antioxidant and skin-smoothing benefits.

Evidence: In vivo studies using 2% phytic acid in AHA formulations demonstrated a measurable decrease in hyperpigmentation after six weeks of treatment.

TRANEXAMIC ACID (INCI: TRANEXAMIC ACID)

Acts as a targeted regulator of pigment overproduction. It inhibits the plasmin-mediated inflammatory cascade that stimulates melanocytes via keratinocyte signaling. B y b locking this pathway, TXA reduces post-inflammatory and UV-induced hyperpigmentation.

Evidence: Multiple randomised clinical studies have shown significant improvement in melasma severity after 8–12 weeks of topical application.

Melanin Correcting Serum Ampoules 7 x 2ml

bdr DermaLumin-C Melanin Correcting Serum, are a high performance,, clinical grade skincare treatment designed to target dark spots, hyperpigmentation, and uneven skin tone. They act as a potent brightening treatment for sun damaged or stressed skin.

A focused & transformative specialty treatment to specifically regulate excessive melanin production. Studies show a visible reduction in dark spots, a more even tone and a regenerated, almost rejuvenated complexion after just 14 days.

Watch a bdr treatment